Lido Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Lido Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$134K	Hold	300	–	–	﹤0.01%	1828
2025 Q4	$136K	Hold	300	–	–	﹤0.01%	1821
2025 Q3	$117K	Hold	300	–	–	﹤0.01%	1743
2025 Q2	$134K	Sell	300 -1,000	-77%	-$461K	﹤0.01%	1569
2025 Q1	$630K	Hold	1,300	–	–	﹤0.01%	946
2024 Q4	$524K	Hold	1,300	–	–	﹤0.01%	996
2024 Q3	$605K	Hold	1,300	–	–	﹤0.01%	892
2024 Q2	$609K	Sell	1,300 -200	-13%	-$86.8K	﹤0.01%	863
2024 Q1	$627K	Hold	1,500	–	–	﹤0.01%	828
2023 Q4	$610K	Hold	1,500	–	–	﹤0.01%	787
2023 Q3	$522K	Buy	+1,500	New	+$525K	﹤0.01%	733

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lido Advisors's VRTX Position: Q1 2026 in Review

Lido Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q1 2026, selling an estimated $4.7M and leaving 43,511 shares worth $19.4M. The position accounts for 0.06% of the portfolio, ranked #207.

Lido Advisors first reported a position in VRTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $22.1M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Lido Advisors held 43,511 shares of Vertex Pharmaceuticals worth $19.4M as of Q1 2026.
Lido Advisors sold 10,086 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.7M.
Vertex Pharmaceuticals made up 0.06% of Lido Advisors's portfolio in Q1 2026, its #207 holding.
Lido Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
Lido Advisors's Vertex Pharmaceuticals position peaked at $22.1M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.